Ray Comenzo

2.5k total citations · 1 hit paper
17 papers, 1.1k citations indexed

About

Ray Comenzo is a scholar working on Molecular Biology, Genetics and Hematology. According to data from OpenAlex, Ray Comenzo has authored 17 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 5 papers in Genetics and 4 papers in Hematology. Recurrent topics in Ray Comenzo's work include Amyloidosis: Diagnosis, Treatment, Outcomes (15 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Multiple Myeloma Research and Treatments (4 papers). Ray Comenzo is often cited by papers focused on Amyloidosis: Diagnosis, Treatment, Outcomes (15 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Multiple Myeloma Research and Treatments (4 papers). Ray Comenzo collaborates with scholars based in United States, Italy and United Kingdom. Ray Comenzo's co-authors include Giampaolo Merlini, Morie A. Gertz, Vaishali Sanchorawala, Alan Solomon, Orhan Sezer, Rodney H. Falk, Pierre Ronco, Jean Paul Fermand, Philippe Moreau and G Grateau and has published in prestigious journals such as Journal of Clinical Oncology, Leukemia and American Journal of Hematology.

In The Last Decade

Ray Comenzo

16 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis

2005 992 citations Morie A. Gertz, Ray Comenzo et al. American Journal of Hematology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ray Comenzo United States	6	1.1k	366	287	224	216	17	1.1k
Steve R. Zeldenrust United States	7	949 0.9×	312 0.9×	265 0.9×	239 1.1×	188 0.9×	9	1000
Darren Foard United Kingdom	11	904 0.8×	199 0.5×	327 1.1×	213 1.0×	219 1.0×	38	930
Kathleen T. Finn United States	11	1.2k 1.1×	245 0.7×	485 1.7×	265 1.2×	309 1.4×	28	1.3k
Caryn Libbey United States	8	923 0.8×	252 0.7×	229 0.8×	173 0.8×	211 1.0×	10	994
Kyle Ra United States	6	872 0.8×	250 0.7×	198 0.7×	225 1.0×	172 0.8×	8	971
David Lavergne France	9	514 0.5×	200 0.5×	117 0.4×	138 0.6×	84 0.4×	18	581
David F. Hutt United Kingdom	13	1.1k 1.0×	575 1.6×	75 0.3×	257 1.1×	95 0.4×	29	1.3k
Sébastien Bender France	16	552 0.5×	289 0.8×	181 0.6×	106 0.5×	36 0.2×	36	756
Nagaaki Katoh Japan	14	379 0.3×	133 0.4×	80 0.3×	162 0.7×	82 0.4×	61	647
James E. Hoffman United States	13	318 0.3×	52 0.1×	126 0.4×	200 0.9×	51 0.2×	68	579

Countries citing papers authored by Ray Comenzo

Since Specialization

Citations

This map shows the geographic impact of Ray Comenzo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ray Comenzo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ray Comenzo more than expected).

Fields of papers citing papers by Ray Comenzo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ray Comenzo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ray Comenzo. The network helps show where Ray Comenzo may publish in the future.

Co-authorship network of co-authors of Ray Comenzo

This figure shows the co-authorship network connecting the top 25 collaborators of Ray Comenzo. A scholar is included among the top collaborators of Ray Comenzo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ray Comenzo. Ray Comenzo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Mico, Vasil, et al.. (2025). Teclistamab in relapsed/refractory systemic AL amyloidosis.. Journal of Clinical Oncology. 43(16_suppl). 7562–7562.

Kastritis, Efstathios, Angela Dispenzieri, Ashutosh Wechalekar, et al.. (2020). Ixazomib-dexamethasone (Ixa-Dex) vs physician’s choice (PC) in relapsed/refractory (RR) primary systemic AL amyloidosis (AL) patients (pts) by prior proteasome inhibitor (PI) exposure in the phase III TOURMALINE-AL1 trial.. Journal of Clinical Oncology. 38(15_suppl). 8546–8546. 7 indexed citations

Zhou, Ping, et al.. (2019). Seeking light-chain amyloidosis very early: The SAVE trial—identifying clonal lambda light chain genes in patients with MGUS or smoldering multiple myeloma.. Journal of Clinical Oncology. 37(15_suppl). 8010–8010. 4 indexed citations

Comenzo, Ray, Efstathios Kastritis, Mathew S. Maurer, et al.. (2019). S875 SUBCUTANEOUS DARATUMUMAB + CYCLOPHOSPHAMIDE, BORTEZOMIB, AND DEXAMETHASONE (CYBORD) IN PATIENTS WITH NEWLY DIAGNOSED AMYLOID LIGHT CHAIN (AL) AMYLOIDOSIS: UPDATED SAFETY RUN‐IN RESULTS OF ANDROMEDA. HemaSphere. 3(S1). 392–392. 10 indexed citations

Godara, Amandeep, et al.. (2019). Combined use of two monoclonal antibodies in patients with systemic AL amyloidosis and cardiac involvement.. Journal of Clinical Oncology. 37(15_suppl). 8009–8009. 4 indexed citations

Comenzo, Ray, Efstathios Kastritis, Mathew S. Maurer, et al.. (2018). Subcutaneous daratumumab (DARA SC) plus cyclophosphamide, bortezomib, and dexamethasone (CyBorD) in patients (Pts) with newly diagnosed amyloid light chain (AL) amyloidosis: Safety run-in results of andromeda.. Journal of Clinical Oncology. 36(15_suppl). 8011–8011. 8 indexed citations

Chari, Ajai, Attaya Suvannasankha, Joseph W. Fay, et al.. (2017). Phase 1b Study of Daratumumab plus Pomalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (RRMM) with ≥2 Prior Lines of Therapy. Clinical Lymphoma Myeloma & Leukemia. 17(1). e14–e15. 1 indexed citations

Merlini, Giampaolo, Isabelle Lousada, Yukio Ando, et al.. (2016). Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis. Leukemia. 30(10). 1979–1986. 66 indexed citations

Chaulagain, Chakra P., Xun Ma, Parul Doshi, et al.. (2015). Pre-clinical translational studies of daratumumab in patients with myeloma or AL amyloidosis undergoing autologous hematopoietic stem cell transplantation (SCT).. Journal of Clinical Oncology. 33(15_suppl). 8587–8587. 2 indexed citations

10.

Merlini, Giampaolo, et al.. (2015). Phase 3 study of the oral proteasome inhibitor ixazomib for relapsed/refractory AL amyloidosis: TOURMALINE-AL1. Clinical Lymphoma Myeloma & Leukemia. 15. e60–e61. 1 indexed citations

11.

Liedtke, Michaela, Heather Landau, Ray Comenzo, et al.. (2015). NEOD001 Demonstrates Cardiac and Renal Biomarker Responses in a Phase 1/2 Study in Patients With AL Amyloidosis and Persistent Organ Dysfunction. Journal of Cardiac Failure. 21(8). S15–S15. 3 indexed citations

12.

Liedtke, Michaela, Giampaolo Merlini, Heather Landau, et al.. (2015). The VITAL study: A randomized, double-blind, placebo-controlled, global, phase III study of NEOD001 in patients with AL amyloidosis and cardiac dysfunction.. Journal of Clinical Oncology. 33(15_suppl). 8614–8614. 2 indexed citations

13.

Gertz, Morie A., Heather Landau, Ray Comenzo, et al.. (2015). Cardiac and renal biomarker responses in a phase 1/2 study of NEOD001 in patients with AL amyloidosis and persistent organ dysfunction.. Journal of Clinical Oncology. 33(15_suppl). 8514–8514. 10 indexed citations

14.

Lousada, Isabelle, Ray Comenzo, Heather Landau, Spencer Guthrie, & Giampaolo Merlini. (2015). Patient Experience With Light Chain Amyloidosis: A Survey From the Amyloidosis Research Consortium. Journal of Cardiac Failure. 21(8). S63–S63. 4 indexed citations

15.

Reece, DE, Ute Hegenbart, Vaishali Sanchorawala, et al.. (2010). Weekly and twice-weekly bortezomib in AL amyloidosis: Results of a phase II study.. Journal of Clinical Oncology. 28(15_suppl). 8023–8023. 1 indexed citations

16.

Gertz, Morie A., Ray Comenzo, Rodney H. Falk, et al.. (2005). Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis. American Journal of Hematology. 79(4). 319–328. 992 indexed citations breakdown →

17.

Falk, R H, et al.. (1998). The effect of cardiac involvement on the outcome of intravenous melphalan therapy and autologous stem cell rescue for AL amyloidosis. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact